Details
Description
Inclusion Criteria
Exclusion Criteria
Details
Title Phase II Randomized Trial of Nivolumab with or without Ipilimumab in Patients with Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer.
IRB NRG-GY003
Hospital Fairview, Hillcrest, Main Campus
Phase Phase 2
Disease Fallopian Tube, Gynecologic, Ovarian, Peritoneal
Drug Ipilimumab, Nivolumab
